Michael Rosenblatt

Michael Rosenblatt, M.D., has held major leadership roles in academia and the biopharmaceutical industry, and currently serves as Senior Partner of Flagship Pioneering in Cambridge, MA. Dr. Rosenblatt was Chief Medical Officer (CMO) for Merck from 2009-2016. Earlier (his first of two times at Merck), he was SVP for Research at Merck Research Laboratories where he co-led the development of alendronate (FOSAMAX), now the leading therapy worldwide for osteoporosis. Additionally, he directed drug discovery efforts in molecular biology, bone biology, virology, cancer research, gastroenterology, ophthalmology, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy.